Hepatitis and Retrovirus

LIAISON® XL murex recHTLV-I/II
Total automation for HTLV-I/II screening and diagnosis
Hepatitis and Retrovirus

Third generation assay for an improved detection of HTLV-I/II infections

Clinical background

HTLV (Human T-cell lymphotropic virus), infects a type of white blood cell called a T-cell or T-lymphocyte. There are two types of HTLV, HTLV-I and HTLV-II, closely related human C retroviruses. HTLV-I is known to cause a type of cancer, referred to as adult T-cell leukemia and lymphoma, and a demyelinating disease called HTLV-I associated myelopathy/Tropical spastic paraparesis (HAM/TSP). HTLV-II has been associated with rare lymphoproliferative diseases and neurodegenerative disorders, although its etiological role remains to be fully established. It is estimated that 15-20 million people are currently infected with human T-cell lymphotropic virus type 1 (HTLV-I) worldwide. HTLV-I is endemic in the Caribbean, Japan, South America, and parts of Africa. HTLV-II is found among native Americans.

HTLV-I/II screening and diagnosis

Transmission of both HTLV I and II occurs through sexual contact, exposure to blood, transfusion of infected cellular blood components and perinatally, probably by breast feeding. The screening of antibodies against HTLV-I/II is an aid in the diagnosis of HTLV infection and is aimed at curbing the risk of transmitting the infection. The LIAISON® XL murex reHTLV-I/II is a third generation assay that utilizes recombinant proteins and synthetic peptides able to recognize antibodies directed to both HTLV-I and HTLV-II. It is configured in a sandwich assay format and with its excellent performance, equivalent to the benchmarked assay Murex HTLV-I/II ELISA, it is an effective test for the diagnosis of HTLV-I/II infection and also for blood donor screening.

Main Features

- Number of tests: 200
- Solid phase & conjugate: recombinant antigens and synthetic peptides
- Label: isoluminol derivative
- Method: CLIA
- Assay format: Sandwich

Ordering information

LIAISON® XL murex reHTLV-I/II (code 310270)
LIAISON® XL murex Control reHTLV-I/II (code 310271)

*Flexibility enables quick and reliable results

- Diagnostic Specificity (5,013 blood donors): 99.94% (95% C.I.: 99.83 - 99.98%)
- Diagnostic Sensitivity (on a total of 894 HTLV-I and HTLV-II samples): 100% (95% C.I.: 99.6 - 100%)
- Sample volume (serum and plasma): 100 µL plus 150 µL dead volume
- Reagent stability on board: 7 weeks
- One-point recalibration, stable for 7 weeks

Product availability subject to required regulatory approval